Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan

Li Kai Tsai, Huey Juan Lin, Su Kiat Chua, Pen Chih Liao, Yuan Po Yang, Ping Chen Chou, Chun Wei Lee, Mao Jen Lin, Hsi Ming Chen, Jung Tze Yeh, Yi Heng Li

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

Background: This study aims to observe the effectiveness and safety of idarucizumab in dabigatran-treated patients with severe bleeding or requiring surgery in Taiwan. Methods and Results: In Taiwan, 11 dabigatran-treated patients developed severe bleeding, fracture that needed surgery, and acute ischemic stroke requiring thrombolysis. These patients were treated with idarucizumab and obtained adequate hemostasis. Our experiences reconfirmed the efficacy and safety of idarucizumab in Asian patients. Conclusions: Idarucizumab improves safety in dabigatran-treated patients. Continued education about the availability and appropriate use of idarucizumab is necessary in Asia.

Original languageEnglish
Pages (from-to)e27-e33
JournalJournal of Stroke and Cerebrovascular Diseases
Volume27
Issue number2
DOIs
Publication statusPublished - 2018 Feb

All Science Journal Classification (ASJC) codes

  • Surgery
  • Rehabilitation
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan'. Together they form a unique fingerprint.

Cite this